Back Pain News and Research

Latest Back Pain News and Research

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

Bedside screening tool can help diagnose acute aortic dissection

The most lethal and sudden cardiovascular event can be the toughest for doctors to diagnose. But a study by the University of Michigan Cardiovascular Center shows new guidelines are effective for determining who's most likely suffering from an aortic dissection, which is tearing in the lining of the body's largest blood vessel.

16 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced that the Company's Zhibai Dihuang Pill and Ciwujia Tablet have been approved for sale as traditional Chinese medicine in Hong Kong by Chinese Medicine Council of Hong Kong.

10 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

$Hyponatremia linked to high risk of fractures in elderly patients$

Hyponatremia linked to high risk of fractures in elderly patients

A common blood disorder, hyponatremia, may be a risk factor for fractures in elderly patients, new research presented at the European Congress of Endocrinology shows.

3 May 2011

OU-COM receives Osteopathic Heritage Foundation grant to address healthcare issues

The Osteopathic Heritage Foundations' $105 million award to Ohio University's College of Osteopathic Medicine represents the largest private donation ever given to a college or university in Ohio. This gift will be used to address some of the most pressing health care issues across the state and the nation - the impending shortage of primary care physicians and the diabetes epidemic.

2 May 2011

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Eli Lilly Canada announced today that Health Canada has approved Cymbalta for the management of chronic low back pain.

30 Apr 2011

Zimmer launches UniWallis Posterior Dynamic Stabilization System in Europe and Asia Pacific

Zimmer Holdings, Inc., a global leader in musculoskeletal care, today announced the launch of the next generation of its Wallis® Posterior Dynamic Stabilization System, the UniWallis™ System, in Europe and Asia Pacific. Since the debut of the Wallis System in 2000, feedback collected from surgeons revealed the need for a device that maintains all of the clinical advantages of the Wallis System, provides improved ease of use and offers a more anatomy-sparing procedure.

29 Apr 2011

Patients of orthopedists are more apt to undergo back surgery

When doctors own or lease MRI equipment, their patients are more likely to receive scans for low back pain. Patients of orthopedists are more apt to undergo back surgery as well, according to a study published online in Health Services Research.

26 Apr 2011

SI-BONE receives FDA approval for updated iFuse Implant System

SI-BONE, Inc., a medical device company that is pioneering the use of a minimally invasive surgical device to treat the sacroiliac joint announced the U.S. Food and Drug Administration approved a major modification to the existing product label.

26 Apr 2011

Physiotherapy Associates inaugurates new clinic in Grand Haven, MI

Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, recently opened a new physical therapy clinic in Grand Haven, MI.

22 Apr 2011

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 11/010,828 entitled "Sustained Release Aminopyridine Composition."

20 Apr 2011

Patients with low back pain can benefit from immediate physiotherapy

Immediate treatment by a physiotherapist, bypassing a waiting list, can reduce problems with recurring low back pain, reveals a thesis from the University of Gothenburg, Sweden.

19 Apr 2011

Chicago doctor develops new non-surgical procedure to alleviate back pain

Dr. Jeff Winternheimer of the Illinois Back Institute has developed a revolutionary non-surgical procedure to alleviate back pain. Both professional athletes and everyday back and neck pain sufferers have been flocking to his four Chicago area clinics to see for themselves.

15 Apr 2011

Positive results from laquinimod Phase III ALLEGRO study in multiple sclerosis to be presented at AAN

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today results from the two-year Phase III ALLEGRO study of laquinimod, an oral, once-daily, investigational immunomodulator for the treatment of relapsing forms of multiple sclerosis (MS). These data will be presented as late-breaking research at the Annual Meeting of the American Academy of Neurology (AAN).

12 Apr 2011

Top-line results from DURECT's ELADUR Phase II trial in chronic low back pain

DURECT Corporation announced today top-line results from a Phase II clinical trial in chronic low back pain for ELADUR, DURECT's proprietary investigational transdermal bupivacaine pain patch.

12 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

Alexion Pharmaceuticals, Inc. announced today that the company has submitted marketing applications to the U.S. Food and Drug Administration and the European Medicines Agency for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

7 Apr 2011